Funder: Pfizer Inc.

Due Dates: May 22, 2026 (Submission deadline — full application/proposal)

Funding Amounts: Up to 120,000€ per project; total available budget is approximately 250,000€; project duration up to 26 months

Summary: Supports real-world research on the use, safety, and effectiveness of elranatamab in relapsed/refractory multiple myeloma in Spain.

Key Information: Applicants must be based in Spain; only organizations (not individuals) are eligible.